Loading
INSMED Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 22 May 2025.
INSMED Inc: what insiders have been doing
INSMED Inc is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). The last twelve months, up to 18 October 2026, brought 119 filings signed by 21 insiders.
No insider bought on the market over the period, while 9 insiders filed 50 sales totalling €68.0M. The amount is not disclosed for 6 filings. At €27.7M, the sale published on 12 August 2026 by Adsett Roger is the largest of the period (0.12% of market cap).
The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
For context, the typical company on the same exchange (median of 5,458 companies) published 22 filings over the same period, against 119 filings here. Over the whole record (from 2016), the tally stands at 7 purchases and 142 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 606.4 m USD and net income at -1.28 bn USD.
Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
383
Thresholds
n/a
Buy Volume
€2M
7 ops. · all time
Sell Volume
€88M
142 ops. · all time
Who traded when
BuySaleWilliam Lewis24 sales
Roger Adsett15 sales
Martina M.D. Flammer12 sales
Smith Michael Alexander11 sales
Bonstein Sara9 sales
Schaeffer Orlov S Nicole5 sales
+6 other insiders
Since the insiders bought
- +61.2%Entry US$67.53 · Close at T+365 US$108.87
- -45.6%Entry US$33.45 · Close at T+365 US$18.20
- -45.6%Entry US$33.45 · Close at T+365 US$18.20
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate INSMED Inc Strong Buy (bullish), based on 23 analysts. Average price target: US$199.04.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 17,950 of 24,148 companies
35.2
score / 100
Value23
Quality48
FCF yld-3.8%
Earn yld-5.0%
EV/EBITDA·
ROE-87%
Gross mgn80%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$117.67
Analyst consensus
23 analystsStrong buy
US$169.00Target US$199.04(+69%)US$243.00
Income statement
RevenueUS$606.4M
Gross profitUS$483.5M80% margin
EBITDA-US$1.2B-194% margin
Net income-US$1.3B-76.9% margin
Valuation
PER (forward)151.9x
P/Book33.9x
Beta0.82
Balance sheet & cash
Market capUS$25.7B
Total debtUS$586.7M
Free Cash Flow-US$967.6M
Debt / Equity98%
Profitability & ownership
ROE-87.2%
ROA-22.2%
% insiders0.5%
% institutions105.0%
Last declaration on 11 September 2026
Declarations383 total
25,000 shares@ US$124.000.012% mcap50.0% of flowCommon StockSEC:0001609305-26-000009:0
25,000 shares@ US$123.98920.012% mcap50.0% of flowcommonSEC144:0001957799-26-000171
5,000 shares@ US$127.530.0024% mcap100.0% of flowCommon StockSEC:0001182633-26-000010:0
5,000 shares@ US$127.52740.0024% mcap100.0% of flowCOMMONSEC144:0001628280-26-057378
82,280 shares@ US$13.670.0043% mcap3.0% of flowCommon StockSEC:0001685904-26-000014:0
76,600 shares@ US$17.160.0050% mcap3.5% of flowCommon StockSEC:0001685904-26-000014:1
80,970 shares@ US$30.460.0094% mcap6.5% of flowCommon StockSEC:0001685904-26-000014:2
239,850 shares@ US$133.270.12% mcap84.7% of flowCommon StockSEC:0001685904-26-000014:3
239,850 shares@ US$133.26330.12% mcap100.0% of flowCommonSEC144:0001628280-26-055394
18,278 shares@ US$18.950.0013% mcap7.4% of flowCommon StockSEC:0001796960-26-000020:0
8,895 shares@ US$25.830.0009% mcap4.9% of flowCommon StockSEC:0001796960-26-000020:1
8,895 shares@ US$127.000.0043% mcap24.1% of flowCommon StockSEC:0001796960-26-000020:2
18,278 shares@ US$129.400.0090% mcap50.5% of flowCommon StockSEC:0001796960-26-000020:3
27,173 shares@ US$128.61130.013% mcap93.0% of flowCommonSEC144:0001628280-26-054303
4,828 shares@ US$105.620.0020% mcap6.3% of flowCommon StockSEC:0001402051-26-000042:2
5,872 shares@ US$106.430.0024% mcap7.7% of flowCommon StockSEC:0001402051-26-000042:3
4,440 shares@ US$17.160.0003% mcap0.9% of flowCommon StockSEC:0001402051-26-000042:1
6,260 shares@ US$30.460.0007% mcap2.4% of flowCommon StockSEC:0001402051-26-000042:0
10,700 shares@ US$106.06230.0044% mcap30.2% of flowCommonSEC144:0001628280-26-049413
4,440 shares@ US$17.160.0003% mcap1.8% of flowCommon StockSEC:0001402051-26-000040:1
5,005 shares@ US$116.550.0023% mcap13.9% of flowCommon StockSEC:0001402051-26-000040:2
2,335 shares@ US$117.620.0011% mcap6.5% of flowCommon StockSEC:0001402051-26-000040:3
3,359 shares@ US$118.520.0015% mcap9.5% of flowCommon StockSEC:0001402051-26-000040:4
6,259 shares@ US$30.460.0007% mcap4.5% of flowCommon StockSEC:0001402051-26-000040:0
10,699 shares@ US$117.39690.0049% mcap33.4% of flowCommonSEC144:0001628280-26-047798
25 of 383 declarations
About INSMED Inc
Insmed Inc. (NASDAQ: INSM) is a U.S.-based biopharmaceutical company headquartered in Bridgewater, New Jersey, in the United States. Founded in 1988, the company has evolved from an earlier-stage developer into a focused respiratory-disease platform spanning marketed products and an active late-stage pipeline. For French-speaking investors in France, Belgium, and Switzerland, Insmed is best understood as a growth-oriented specialty pharma/biotech company: it already has commercial assets, but a significant part of its equity story still depends on clinical execution and regulatory expansion.
The company’s current business is centered on two key products. ARIKAYCE, an inhaled liposomal amikacin product, remains an important commercial franchise and is approved in the United States, Europe, and Japan for patients with MAC lung disease who remain culture-positive after prior multidrug therapy. BRINSUPRI (brensocatib), which received U.S. approval in 2025 and European Commission approval later the same year, is now the company’s most important growth driver. BRINSUPRI is a once-daily oral DPP1 inhibitor for non-cystic fibrosis bronchiectasis, a serious chronic lung disease with historically limited approved treatment options. That approval meaningfully broadens Insmed’s commercial runway and reduces reliance on a single legacy asset over time.
Read moreShow less
Insmed’s competitive position is built on deep expertise in pulmonary and orphan-disease development, especially in areas of high unmet medical need. The company has combined regulatory know-how, clinical development capability, and international commercialization infrastructure. Beyond its marketed portfolio, Insmed is advancing several pipeline programs, including treprostinil palmitil inhalation powder (TPIP) in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, plus additional early-stage initiatives. Recent corporate updates indicate a busy clinical calendar and a strategy aimed at expanding the addressable market beyond bronchiectasis and MAC lung disease.
Geographically, Insmed remains firmly anchored in the United States, with its global headquarters in Bridgewater, New Jersey, but it also maintains offices and research sites across Europe and in Japan. That footprint supports global regulatory filings, regional launches, and longer-term international growth. Recent major milestones include the FDA approval of BRINSUPRI in 2025, the European Union approval in 2025, and positive topline data for TPIP. From an investor’s perspective, Insmed on NASDAQ in the United States offers a combination of commercial momentum, multiple clinical catalysts, and international expansion potential, alongside the usual biotech risks tied to trial outcomes, pricing, reimbursement, and execution.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
